entially slowing its eventual rollout in the fight against the pandemic.
However, the Lancet study gave few extra clues about why efficacy was 62 percent for trial participants given two full doses, but 90 percent for a smaller sub-group given a half, then a full dose.Less than 6 percent of UK trial participants were given the lower dose regimen and none of them was aged over 55, meaning more research will be needed to investigate the vaccine's efficacy in older people who are particularly susceptible to COVID-19.
But the AstraZeneca/Oxford vaccine is seen as particularly important to tackling the pandemic in the developing world, as it would be cheaper and easier to distribute. Asked whether the half, then full dose regimen had been a mistake, Andrew Pollard, director of the Oxford Vaccine Group and chief investigator into the trials, told a news conference it had been "unplanned."
Pangalos also said he assumed U.S. regulators would want to see results from an ongoing trial in the United States before giving their approval.The Oxford researchers said the vaccine was found to be safe, with three out of the roughly 23,700 participants experiencing serious conditions that were possibly related to either the COVID-19 vaccine or a standard meningitis vaccine given to a control group.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.